Kornimate/medical-research-clean huggingface dataset:
investigating utility of ctdna and tumour evolution in advanced thyroid cancer

Conditions: Thyroid Cancer

Summary: although most thyroid cancers are treated and cured successfully there are still 30% who recur after many years. this will eventually progress and at this point may become incurable with treatment options including complex and high risk surgery. the overall efficacy of systemic treatment in advanced thyroid cancer has a good initial response in most patients but not all. the study will collect tissues and blood samples for various protein analysis, nucleic acid extraction and live cell analysis in order to try and detect the presence of plasma ctdna at baseline of eligible patients.

the treatment decisions are based on relying on radiological parameters such as using the recist criteria and measuring the rise in certain serum tumour biomarkers. however, the disadvantage of this is that this method can take many months to detect a change in disease volume. an improved understanding of genetics and cancer and potential gene sequencing can help achieve personalised treatment for patients. however, there are many questions and issues that still need to be answered and require urgent attention before being able to achieve optimate patient stratification. we need to identify better tumour biomarkers to detect disease progression, show real time response to treatment and understand why tumours evolve to becoming more aggressive. this study hopes to address these issues by proposing a multicentre prospective study to investigate the presence and role of ctdna in advanced thyroid cancer including differentiated thyroid cancer , medullary thyroid cancer and anaplastic thyroid cancer.

Eligibility criteria:
inclusion criteria: * age 18 years or older. (all cohorts) * patients diagnosed with radioiodine refractory differentiated thyroid carcinoma (rr-dtc) under surveillance. (cohort 1) * patients with newly diagnosed resectable locally advanced medullary thyroid cancer or patients with newly diagnosed metastatic medullary thyroid cancer for surveillance or patients with locally advanced or metastatic medullary thyroid cancer on surveillance (cohort 2) * patients with rr-dtc starting systemic therapy or patients with rr-dtc on systemic therapy or patients with mtc starting systemic therapy or patients with mtc on systemic therapy (cohort 3) * patients with newly diagnosed anaplastic thyroid cancer (cohort 4) * availability of tissue from one archival diagnostic tumour tissue block or be willing to have biopsy of accessible disease (all cohorts) * patients must be willing to undergo standard monitoring and treatment as recommended by their clinical team (all cohorts) * ability to give informed consent for biological sample collection. (all cohorts) exclusion criteria: * previous or concurrent illness, which in the investigator's opinion would interfere with collection of the complete sample collection * any invasive malignancy within previous 5 years (other than non-melanomatous skin carcinoma or carcinoma in situ) * pregnancy
a trial of intravenous denileukin diftitox in stage iii or iv ovarian cancer

Conditions: Epithelial Ovarian Cancer; Extraovarian Peritoneal Cancer; Fallopian Tube Carcinoma

Summary: this study tests whether denileukin diftitox will deplete regulatory t cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.

this is a non-randomized, single-arm, phase ii trial. selected patients with advanced-stage epithelial ovarian cancers who have no reasonable chance of cure using standard regimens, or who will not receive such regimens (due to contraindication or intolerance) are eligible. patients will be treated with ontak at 12 µg/kg monthly as long as they meet response criteria.

Eligibility criteria:
inclusion criteria: * able to provide informed consent * not on immune modulating drugs * life expectancy less than 6 months exclusion criteria: * unable to tolerate phlebotomy * germ cell or stromal cell cancers of the ovaries * active autoimmune disease

Keywords: epithelial ovarian cancer figo (international fed of gyn and ob)stage iii or stage iv extraovarian peritoneal cancer fallopian tube carcinoma failing
the effect of tranexamic acid. a randomised study of patients undergoing elective lumbar spine surgery.

Conditions: Pharmacological Action

Summary: in this randomized double blind placebo controlled study of tranexamic acid during minor spinal surgery, mean postoperative blood loss in the patients who received txa was statistically significantly lower compared to placebo.

study design: double-blind, randomized, placebo-controlled, parallel-group study. objective: to investigate the effect of tranexamic acid (txa) compared to placebo in low-risk adult patients undergoing elective minor lumbar spine surgery on operative time, estimated blood loss and complications. summary of background data: studies have shown that txa reduces blood loss during major spine surgery. there are no studies on the effect of txa in minor lumbar spine surgery on operative time, intraoperative and postoperative blood loss and complications. methods: we enrolled patients with asa grades 1 to 2, scheduled to undergo lumbar decompressive surgery at middelfart hospital. patients with thromboembolic disease, coagulopathy, hypersensitivity to txa or history of convulsion were excluded. patients were randomized, in blocks of 10, to two groups: txa or placebo. anticoagulation therapy was discontinued 2-7 days preoperatively. prior to the incision, patients received either a bolus of txa (10mg/kg), or an equivalent volume of saline solution (placebo).

Eligibility criteria:
inclusion criteria: * patients referred to the centre for spine surgery and research in the region of southern denmark with symptomatic, mri-verified lumbar spinal stenosis or disc herniations * low risk (american society of anesthesiologists, asa, score 1-2) adult patients scheduled for elective primary decompression or/and discectomy over one to two vertebral levels (without fusion or instrumentation), willing to give informed consent. exclusion criteria: not able to understand verbal and/or written danish asa score more than 2 malignant disease pregnancy breast feeding contraindications to txa: active thromboembolic disease coagulopathy history of venous or arterial thrombosis hypersensitivity to the active substance disseminated intravascular coagulation severe renal impairment history of convulsions asa - american society of anesthesiologists score, txa - tranexamic acid.

Keywords: txa;decompression; discectomy; operative time; blood loss
chinese eopd registry

Conditions: Parkinson Disease

Summary: the purpose of the chinese early-onst parkinson's disease registry (ceopdr) is to develop a database of persons with early-onset parkinson's disease (eopd) in china.

parkinson's disease (pd) is the second most common disorder among degenerative neurological disease. early-onset pd (eopd) has its unique clinical feature and genetic basis.investigators aim to establish a database of eopd,and characterize the clinical feature, genetic basis, environmental factors and their interactions eopd in china. method: 1. clinical feature will be measured by scales and neurological tests.standard scales includes: unified parkinson's disease rating scale(updrs), hoehn-yahr stages, nmss, mmse, pdss(parkinson disease sleep scales),rapid eye movement sleep behaviour disorder questionnaire(rbdq-hk),ess(epworth sleepiness scale),rome iii functional constipation scale，scopa-aut (the scale for outcomes in pd for autonomic symptoms)，pfs(parkinson fatigue scale)，ch-rlsq，hyposmia rating scale(hrs)hamilt depression scale，the 39-item parkinson's disease questionnaire(pdq-39)，freezing of gait scale(fog)，dyskinesia related scales, wearing-off scale(wo) 2. peripheral blood from patients was collected for whole exome sequencing. 3. the environmental factors are explored by questionnaires including smoking,drinking, pesticide and heavy metals.

Eligibility criteria:
inclusion criteria: * patients diagnosed with pd by ukbb and other standard criteria age of onset is no more than 50 years old. exclusion criteria: * patients have a family history of pd.
motor skill proficiency after equine-assisted activities and brain-building tasks

Conditions: Motor Delay; Motor Skills Disorders; Autism Spectrum Disorder; Attention Deficit Hyper Activity; Intellectual Disability; Sensory Disorders

Summary: there is no current research to support the efficacy of a combination of equine-assisted activities (eaa) and brain building activities to influence motor skill competencies in youth with neurodevelopmental disorders (nd). the primary objective of this study was to quantify changes in motor skill proficiency before and after 8 weeks of eaa and brain-building activities in youth with nd. a secondary objective was to quantify changes in motor skill proficiency before and after 1 year of eaa and brain-building activities in youth with nd.

twenty-five youth completed the same 32-week protocol that was separated into 4, 8-week blocks, in the following order: a) control, b) eaa-only, c) washout, and d) gaitway block (eaa and brain building activities). before and after each block, motor skills were assessed using the short form of the bruininks-oseretsky test of motor proficiency-version 2 (bot-2). seven youth continued with the gaitway intervention for one additional year, and the bot-2 short form was also administered following this intervention. a repeated-measures analysis-of-variance was performed to compare bot-2 subtest and overall scores between interventions. a significance of .05 was used. manual dexterity was higher at post-washout versus pre-control (p = .018) and post-control (p = .024), and at post-gaitway versus pre-control (p = .037). upper-limb coordination was higher post-gaitway versus post-control (p = .050). when compared to pre-control, strength was higher at post-eaa (p = .028) and at post-gaitway (p = .015). overall scores were higher at post-gaitway when compared to pre-control (p = .003) and post-control (p = .009). among the seven participants who participated in the 1-year follow-up gaitway motor skills were maintained for one year following the post-gaitway testing session. a combination of eaa and brain building activities may be an effective therapeutic modality to improve and maintain motor skill proficiency in youth with nd.

Eligibility criteria:
inclusion criteria: * age 5 to 18 years * diagnosis of a neurodevelopmental disorder (as defined by the diagnostic and statistical manual of mental disorders (dsm-5)) * had the ability to follow verbal directions, * clearance to participate from a medical professional exclusion criteria: * a perfect score on the motor proficiency test at the first testing session * presence of seizures within the past 6 months controlled by medication * a known allergy to horses * any surgical procedures performed within the 6 months * regular horseback riding experience of any kind during the past year
admscs for the treatment of systemic sclerosis

Conditions: Systemic Sclerosis

Summary: systemic sclerosis (ssc) is a rare autoimmune disease, mainly characterized by cutaneous and visceral fibrosis. digital ulcer and sclerosing skin are commonly affected on hands, but the treatment for these manifestations are often ineffective. adipose tissue contains stromal vascular fraction (svf), which is abundant multipotent stem cells, capable of tissue repair. a prior study (nct01813279) has shown the safety and tolerance at 6 months of the subcutaneous injection of svf in the fingers in ssc. there are only few ways to manage ssc patients with skin lesion who already have treated with several medications (including vasodilators, pde5 inhibitor, endothelin receptor antagonist) but some times their skin lesions are critical physically and emotionally. autologous svf injection could be one of the treatment options to treat skin lesion of ssc. thus, the investigators study the efficacy and potential adverse event in korean patients with ssc.

in this study, the investigators will inject autologous stromal vascular fraction. 1) acquiring autologous stromal vascular fraction by plastic surgeon 1. liposuction 2. extraction and purifying svf using smart-x system (15-20 min) 3. making syringe filled with autologous svf 2) svf injection inject svf subcutaneously with 25g needle in finger

Eligibility criteria:
inclusion criteria: 1. patients who fulfill 2013 american college of rheumatology/ european league against rheumatism criteria for the classification of systemic sclerosis. 2. the skin lesion was not improved after 6 months treatment with conventional therapy. exclusion criteria: 1. pregnancy 2. start new medications within 3 months prior to enrollment 3. previous sympathectomy or amputation 4. current systemic infection 5. aids, syphilis, hepatitis b\&c 6. bmi \<17kg/m2 7. cognitive dysfunction and other psychologic problems

Keywords: systemic sclerosis adipose derived stem cell stromal vascular fraction digital ulcer gangrene
a neoadjuvant study of tislelizumab and sx-682 for resectable pancreas cancer

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-pd-1 antibody) in combination with sx-682 (a cxcr1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.


Eligibility criteria:
inclusion criteria: * ability to understand and willingness to sign a written informed consent document. * age ≥18 years. * newly diagnosed have histologically or cytologically proven adenocarcinoma of the pancreas. * tumor must be resectable. * patient's acceptance to have a tumor biopsy. * ecog performance status 0 or 1 * patients must have adequate organ and marrow function defined by study-specified laboratory tests. * for both women and men, must use acceptable form of birth control while on study. exclusion criteria: * have received any anti-pancreatic cancer therapy. * have been diagnosed with another malignancy whose natural history or treatment has the potential to interfere with safety or efficacy assessment of this study. * conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures * subjects with active, known or suspected autoimmune disease that may relapse. * systemic steroid therapy (\> 10mg daily prednisone equivalent) or immunosuppressive therapy within 14 days of first dose of study drug administration. * active infection requiring systemic therapy. * infection with hiv or hepatitis b or c at screening• * history of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc. * uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, pulmonary embolism, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements. * prior allogeneic stem cell transplantation or organ transplantation * any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drug. * have received a live vaccine ≤ 28 days before first dose of study drug. * use of qt prolonging drugs within 2 weeks before the start of sx-682 dosing and for the length of the study. * ecg demonstrating a qtc interval ≥ 470 msec or patients with congenital long qt syndrome. * severe hypersensitivity reaction to any monoclonal antibody. * concurrent participation in another therapeutic clinical study * pregnant or breastfeeding

Keywords: pancreatic cancer adenocarcinoma resectable pancreas cancer tislelizumab anti-pd-1 pd-l1 antibody sx-682 cxcr1/2 (chemokine receptor) cxcr1/2 inhibitor small molecule immunotherapy
a study to compare the effectiveness of two types of ultrasound technologies in women who have had breast cancer

Conditions: Malignant Breast Neoplasm

Summary: this clinical trial evaluates automated breast ultrasound (abus) and handheld ultrasound (hhus) for the screening of women who have undergone breast reconstruction after breast cancer. ultrasounds use high-frequency sound waves to create pictures of internal organs and tissues. abus has been found to be equal to hhus for whole breast screening, but no data exist on its use for screening of reconstructed patients. this clinical trial evaluates the feasibility of using abus versus hhus to screen women who have undergone reconstruction.

primary objective: i. to show that abus reduces artifact compared to hhus in terms of detection of the residual tissue in reconstructed nipple sparing mastectomy (nsm) and skin sparing mastectomy (ssm) patients. secondary objectives: i. to evaluate both the performance and interpretation times for abus and hhus so that these factors can be considered when scheduling patients and for ease of implementation into practice. ii. a short survey will be administered immediately after both ultrasounds performed to enrolled patients to assess their experience with hhus and abus, specifically addressing their perceived comfort level on a numerical scale and if they would be interested in obtaining subsequent annual screening hhus or abus. exploratory objective: i. the appearance of native and reconstructed anatomy on abus and hhus will be studied. outline: participants undergo hhus and abus in no required order over 1 hour. participants with ultrasound results indicating breast imaging reporting and data system (bi-rads) 4 or 5 (suspicious and needs biopsy) undergo biopsy within 30 days.

Eligibility criteria:
inclusion criteria: * female * \>= 18 years of age at time of consent * free of focal breast symptoms and with no suspicious breast physical exam findings * previous unilateral nsm or ssm with implant (silicone, saline) or flap reconstruction performed at thomas jefferson university hospital * must be able to understand and provide signed and dated informed consent form. if a patient understands the informed consent but is unable to sign, a legally authorized representative (lar) may sign * willing to comply with all study procedures and be available for the duration of the study * willing to honor any bills that may be incurred if the insurance company does not pay for the billed bilateral hand held ultrasound exclusion criteria: * history of breast cancer recurrence * current focal breast symptoms since nsm or ssm with reconstruction * nsm or ssm with reconstruction was performed years prior to study enrollment * bilateral nsm or ssm with reconstruction * females who are pregnant
a real-time magnetic device prototype for temporary management of paralytic lagophthalmos

Conditions: Paralytic Lagophthalmos

Summary: to develop a real-time wearable device based on the principle of magnetic force for temporary management of lagophthalmos, and evaluate its efficacy and safety, including synchronous blinks and eye closure, blurred vision, foreign body sensation over cornea or eyeball, burning or hot sensation over facial skin, and erythema or pruritus over eyelid, by performing a human trial on patients with lagophthalmos.

the wearable system includes a near-infrared (nir) light-emitting diode (smt910, epitex inc, kyoto, japan) and receiver (pd15-22c tr8, everlight electronics corporation, new taipei city, taiwan), a permanent electromagnetic actuator (jnp-12/12, joint magnetic technology corporation, shenzhen, china), an iron sheet affixed to the paralytic upper eyelid, and a bio-signal acquisition module together with a power supply unit providing a wired connection to the nir sensor and permanent electromagnetic actuator. the palpebral gap was measured before and after the wearing of the device. the efficacy of the device prototype was assessed in terms of synchronous blinks and eye closure. subjective sensation and complications were assessed by blurred vision, foreign body sensation over cornea or eyeball, burning or hot sensation over facial skin, and erythema or pruritus over eyelid. after the completion of the study procedure, eyelid skin condition was examined.

Eligibility criteria:
inclusion criteria: * patient with unilateral lagophthalmos; they are capable of understanding and complying with protocol requirements * aged 18 years old or older exclusion criteria: * upper eyelid scar, contracture, fibrosis, and atrophy due to previous surgical intervention(s) or traffic accident * patients with psychiatric (or mental) disorders; they are unable to cooperate or follow the study procedure * children younger than 18 years of age

Keywords: lagophthalmos incomplete eye closure magnetic device blink restoration facial nerve palsy
bromfenac 0.09% vs ketorolac 0.4% for cyclosporine induction phase

Conditions: Dry Eye Disease; Ocular Comfort

Summary: to compare bromfenac 0.09% and ketorolac 0.4% when used concomitantly with cyclosporine ophthalmic emulsion 0.05% in improving patient comfort during the induction phase of treatment for chronic dry eye disease


Eligibility criteria:
inclusion criteria: * must be in general good health * diagnosis of moderate to severe dry eye syndrome exclusion criteria: * patients who are unlikely to respond to cyclosporine ophthalmic emulsion therapy * patients who are pregnant or nursing females * unwilling to discontinue use of contact lenses during the run-in and duration of the study * presence or history of any systemic or ocular disorder or condition that could possibly interfere with the interpretation of the study results in the study eye * previous treatment failure on csa 0.05% (restasis) * known hypersensitivity to any component of the study or procedural medications * participation in any other clinical trial within 30 days prior to screening * known contraindication to any study medication or any of their components. * should not be taking any oral anti-histamines, beta blockers or diuretics.